Product Description

Mounjaro contains Tirzepatide 5 mg, a dual GIP and GLP-1 receptor agonist developed by Eli Lilly. It is FDA-approved for the treatment of type 2 diabetes in adults and is showing promising results in clinical trials for obesity and weight loss management.

Mounjaro helps control blood sugar levels while also supporting weight reduction in adults when used alongside diet and exercise. It is administered as a once-weekly subcutaneous injection.

Key Benefits

• Improves blood sugar control in type 2 diabetes
• Promotes significant weight loss
• Once-weekly dosing with prefilled pen
• Dual hormone action (GIP + GLP-1)
• Reduces appetite and improves insulin sensitivity

Product Details

• Generic Name: Tirzepatide
• Strength: 5 mg per dose
• Form: Prefilled Pen Injector
• Dosage Form: Subcutaneous Injection
• Packaging: 1 Pen (Single Dose) or as prescribed
• Storage: Refrigerate between 2°C–8°C. Do not freeze.

Dosage & Administration

• Start with 2.5 mg once weekly for 4 weeks (starter dose)
• Then increase to 5 mg once weekly as prescribed
• Inject subcutaneously in the thigh, abdomen, or upper arm
• Can be administered at any time of day, with or without meals

Warnings & Precautions

• Not recommended for patients with a history of medullary thyroid cancer or MEN syndrome
• May cause gastrointestinal side effects like nausea, vomiting, or diarrhea
• Consult your doctor if you have pancreatitis, kidney, or liver issues
• Monitor blood sugar if used with insulin or other antidiabetics

FAQs

1. What is Mounjaro 5 mg used for?

Mounjaro is primarily used to manage type 2 diabetes and is also effective in aiding weight loss.

2. How quickly does Mounjaro start working?

Blood sugar improvement may be seen within weeks; weight loss benefits are usually noticeable after a few months.

3. Is Mounjaro approved for weight loss?

While it is FDA-approved for type 2 diabetes, it is used off-label for weight loss under medical supervision.

4. What are the common side effects?

Nausea, diarrhea, decreased appetite, vomiting, and constipation are the most common.